DE3782576T3 - Morphologisch homogene Formen von Famotidin und Verfahren zu deren Herstellung. - Google Patents
Morphologisch homogene Formen von Famotidin und Verfahren zu deren Herstellung.Info
- Publication number
- DE3782576T3 DE3782576T3 DE3782576T DE3782576T DE3782576T3 DE 3782576 T3 DE3782576 T3 DE 3782576T3 DE 3782576 T DE3782576 T DE 3782576T DE 3782576 T DE3782576 T DE 3782576T DE 3782576 T3 DE3782576 T3 DE 3782576T3
- Authority
- DE
- Germany
- Prior art keywords
- famotidine
- preparation
- homogeneous forms
- morphologically homogeneous
- morphologically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 title 1
- 229960001596 famotidine Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU863370A HU196775B (en) | 1986-08-05 | 1986-08-05 | Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances |
Publications (3)
Publication Number | Publication Date |
---|---|
DE3782576D1 DE3782576D1 (de) | 1992-12-17 |
DE3782576T2 DE3782576T2 (de) | 1993-03-25 |
DE3782576T3 true DE3782576T3 (de) | 2002-08-08 |
Family
ID=10963778
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE198787306882T Pending DE256747T1 (de) | 1986-08-05 | 1987-08-04 | Morphologisch homogene formen von famotidine und verfahren zu deren herstellung. |
DE3782576T Expired - Lifetime DE3782576T3 (de) | 1986-08-05 | 1987-08-04 | Morphologisch homogene Formen von Famotidin und Verfahren zu deren Herstellung. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE198787306882T Pending DE256747T1 (de) | 1986-08-05 | 1987-08-04 | Morphologisch homogene formen von famotidine und verfahren zu deren herstellung. |
Country Status (18)
Country | Link |
---|---|
US (3) | US4894459A (de) |
EP (1) | EP0256747B2 (de) |
JP (2) | JP2644234B2 (de) |
KR (1) | KR940003954B1 (de) |
CN (1) | CN1024275C (de) |
AR (1) | AR243175A1 (de) |
AT (1) | ATE82274T1 (de) |
AU (1) | AU604040B2 (de) |
BG (1) | BG60496B2 (de) |
CA (1) | CA1265809A (de) |
CS (1) | CS268188B2 (de) |
DE (2) | DE256747T1 (de) |
DK (1) | DK175022B1 (de) |
FI (1) | FI89917C (de) |
GR (1) | GR871216B (de) |
HU (1) | HU196775B (de) |
PH (1) | PH24069A (de) |
PT (1) | PT85473B (de) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL86330A0 (en) * | 1987-06-22 | 1988-11-15 | Marga Investigacion | Famotidine polymorphic forms and their preparation |
CA2166891C (en) * | 1993-07-09 | 2001-07-03 | Sang K. Wong | Method for making freeze dried drug dosage forms |
US6939873B2 (en) * | 2000-07-26 | 2005-09-06 | Taro Pharmaceuticals Industries Limited | Non-sedating barbituric acid derivatives |
US7683071B2 (en) * | 2000-07-26 | 2010-03-23 | Taro Pharmaceuticals Industries Ltd. | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
US6756379B2 (en) | 2001-07-26 | 2004-06-29 | Taro Pharmaceutical Industries Ltd. | Non-sedating barbiturate compounds as neuroprotective agents |
TWI353979B (en) * | 2002-04-10 | 2011-12-11 | Nippon Zoki Pharmaceutical Co | Novel crystal form of 5-hydroxy-1-methylhydantoin |
CA2426122A1 (en) * | 2002-05-02 | 2003-11-02 | M/S Tonira Pharma Limited | A process for the preparation of a combination of famotidine polymorphis a and b |
TW200409746A (en) * | 2002-07-26 | 2004-06-16 | Theravance Inc | Crystalline β2 adrenergic receptor agonist |
CA2505335C (en) | 2002-12-11 | 2013-09-10 | Daniel Aaron Moros | Method of treating movement disorders using barbituric acid derivatives |
TW200510277A (en) * | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
WO2006003651A2 (en) * | 2004-07-02 | 2006-01-12 | Taro Pharmaceutical Industries, Ltd | A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid |
US20080020040A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Unit dose form for administration of ibuprofen |
US20070043097A1 (en) * | 2005-07-18 | 2007-02-22 | Horizon Therapeutics, Inc. | Medicaments containing famotidine and ibuprofen and administration of same |
US20080021078A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
US8067451B2 (en) * | 2006-07-18 | 2011-11-29 | Horizon Pharma Usa, Inc. | Methods and medicaments for administration of ibuprofen |
US8067033B2 (en) | 2007-11-30 | 2011-11-29 | Horizon Pharma Usa, Inc. | Stable compositions of famotidine and ibuprofen |
PL2043637T3 (pl) | 2006-07-18 | 2012-06-29 | Horizon Pharma Usa Inc | Sposoby i leki do podawania ibuprofenu |
US20100297224A1 (en) * | 2006-08-31 | 2010-11-25 | Horizon Therapeutics, Inc. | NSAID Dose Unit Formulations with H2-Receptor Antagonists and Methods of Use |
US7718649B1 (en) | 2006-11-10 | 2010-05-18 | Pisgah Labs, Inc. | Physical states of a pharmaceutical drug substance |
US8039461B1 (en) | 2006-11-10 | 2011-10-18 | Pisgah Laboratories, Inc. | Physical states of a pharmaceutical drug substance |
EP2081576A4 (de) * | 2006-11-14 | 2010-06-30 | Taro Pharmaceuticals North Ame | Verfahren zur verbesserung der bioverfügbarkeit für nichtsedierende barbiturate |
US8883863B1 (en) | 2008-04-03 | 2014-11-11 | Pisgah Laboratories, Inc. | Safety of psuedoephedrine drug products |
TW201011043A (en) * | 2008-06-20 | 2010-03-16 | Chugai Pharmaceutical Co Ltd | Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives |
WO2015163832A1 (en) | 2014-04-25 | 2015-10-29 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. | An ibuprofen and famotidine combined composition having improved stability |
TR201618765A2 (tr) | 2016-12-16 | 2018-07-23 | Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirketi | Ağrı ve enflamasyonun tedavisi için steroid olmayan anti-enflamatuvar ilaçlar ve H2 reseptörü antagonisti kombinasyonları. |
AU2021310264A1 (en) | 2020-07-15 | 2023-02-09 | Schabar Research Associates Llc | Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1543238A (en) * | 1976-09-21 | 1979-03-28 | Smith Kline French Lab | Polymorph of cimetidine |
JPS6056143B2 (ja) * | 1979-08-02 | 1985-12-09 | 山之内製薬株式会社 | アミジン誘導体ならびにその製造法 |
JPS5655383A (en) * | 1979-10-12 | 1981-05-15 | Yamanouchi Pharmaceut Co Ltd | Amizine derivative and its preparation |
HU185457B (en) * | 1981-09-25 | 1985-02-28 | Richter Gedeon Vegyeszet | Process for preparating cimetidine-z |
US4496737A (en) * | 1982-09-27 | 1985-01-29 | Merck & Co., Inc. | Process for preparing sulfamylamidine antisecretory agents |
JPS59227870A (ja) * | 1983-06-07 | 1984-12-21 | Yamanouchi Pharmaceut Co Ltd | 新規2−グアニジノチアゾリン誘導体ならびにその製造法 |
HU194845B (en) * | 1985-09-11 | 1988-03-28 | Richter Gedeon Vegyeszet | Process for production of n-sulphamil-3-/2-guanidintiazolil-4-methil-tio/-propion-amidin |
DE3644246A1 (de) * | 1986-06-20 | 1987-12-23 | Uriach & Cia Sa J | Verfahren zur herstelung von 3-(((2-((aminoiminomethyl)-amino)-4-thiazolyl)-methyl)-thio)-n-(aminosulfonyl)-propanimidamid |
GB8618847D0 (en) * | 1986-08-01 | 1986-09-10 | Smith Kline French Lab | Pharmaceutical formulations |
IL86330A0 (en) * | 1987-06-22 | 1988-11-15 | Marga Investigacion | Famotidine polymorphic forms and their preparation |
-
1986
- 1986-08-05 HU HU863370A patent/HU196775B/hu unknown
-
1987
- 1987-07-29 GR GR871216A patent/GR871216B/el unknown
- 1987-07-30 PH PH35602A patent/PH24069A/en unknown
- 1987-08-03 DK DK198704041A patent/DK175022B1/da not_active IP Right Cessation
- 1987-08-03 PT PT85473A patent/PT85473B/pt unknown
- 1987-08-03 FI FI873346A patent/FI89917C/fi not_active IP Right Cessation
- 1987-08-04 AT AT87306882T patent/ATE82274T1/de not_active IP Right Cessation
- 1987-08-04 EP EP87306882A patent/EP0256747B2/de not_active Expired - Lifetime
- 1987-08-04 CN CN87105373A patent/CN1024275C/zh not_active Expired - Lifetime
- 1987-08-04 KR KR1019870008563A patent/KR940003954B1/ko not_active IP Right Cessation
- 1987-08-04 JP JP62193855A patent/JP2644234B2/ja not_active Expired - Lifetime
- 1987-08-04 CA CA000543728A patent/CA1265809A/en not_active Expired - Lifetime
- 1987-08-04 AR AR87308333A patent/AR243175A1/es active
- 1987-08-04 CS CS875799A patent/CS268188B2/cs not_active IP Right Cessation
- 1987-08-04 DE DE198787306882T patent/DE256747T1/de active Pending
- 1987-08-04 DE DE3782576T patent/DE3782576T3/de not_active Expired - Lifetime
- 1987-08-04 US US07/081,423 patent/US4894459A/en not_active Expired - Lifetime
- 1987-08-04 AU AU76542/87A patent/AU604040B2/en not_active Expired
-
1990
- 1990-04-27 US US07/515,191 patent/US5120850A/en not_active Expired - Lifetime
-
1991
- 1991-07-11 US US07/728,805 patent/US5128477A/en not_active Expired - Lifetime
-
1994
- 1994-01-18 BG BG98384A patent/BG60496B2/bg unknown
- 1994-08-22 JP JP6196865A patent/JP2708715B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3782576T3 (de) | Morphologisch homogene Formen von Famotidin und Verfahren zu deren Herstellung. | |
DE3750760D1 (de) | Modifiziertes Dienpolymer und Verfahren zu seiner Herstellung. | |
DE3887625D1 (de) | Verfahren zur Herstellung von 1,1,1-Trifluorodichlorethan und von 1,1,1,2-Tetrafluorchlorethan. | |
DE3751537D1 (de) | Polypeptid- und Proteinderivate und Verfahren zu deren Herstellung. | |
DE3851586D1 (de) | Zusammensetzung eines spezifischen Blockmischpolymeres und Verfahren zu deren Herstellung. | |
DE68927703D1 (de) | Verfahren zur Herstellung von 2,3-Dimethylbutenen | |
DE68927949D1 (de) | 3,9-Diphosphaspiroundecane und Verfahren zur Herstellung von 3,9-Diphosphaspiroundecanen | |
DE3852426D1 (de) | Gemischter Supraleiter und Verfahren zu seiner Herstellung. | |
DE68912655D1 (de) | Verfahren zur Herstellung von Decabromediphenylalkanen und Decabromdiphenylethan. | |
DE69020797D1 (de) | Lösung von hochmolekularen Polycarbodiimiden sowie Verfahren zu deren Herstellung. | |
ATE104666T1 (de) | Abkoemmlinge von benzocycloalkenyldihydroxyalkansaeuren, verfahren zu deren herstellung und diese enthaltende pharmazeutika. | |
DE68920814D1 (de) | Verfahren zur Herstellung von Galaktooligosacchariden. | |
DE69118002D1 (de) | Verfahren zur Herstellung von 1,1,1-Trifluorchlorethan und 1,1,1,2-Tetrafluorethan | |
ATE112568T1 (de) | Verfahren zur herstellung von 9-substituierten guaninderivaten und zwischenprodukte zur verwendung im verfahren. | |
DE69024835D1 (de) | Verfahren zur Herstellung von Bisimidprodukten | |
DE68920063D1 (de) | Derivate von Benzoesäure und Verfahren zu deren Herstellung. | |
DE68917372D1 (de) | Verfahren zur Herstellung von Nde I-Restriktionsendonuklease und Methylase. | |
DE59004582D1 (de) | 1,3-Di-arylmethoxy-4,6-dinitrobenzole, Verfahren zu ihrer Herstellung und Verfahren zur Herstellung von 4,6-Diaminoresorcin. | |
DE3674585D1 (de) | Zubereitung zur behandlung und vorbeugung von diarrhoee bei menschen und tieren und verfahren zu deren herstellung. | |
DE59009107D1 (de) | 1-E3-(2-Hydroxy-3-alkylaminopropoxy)-2-thienyl]-3-phenyl-1-propanone und Verfahren zu deren Herstellung. | |
DE3788031D1 (de) | Harzzusammensetzungen und Verfahren zu deren Herstellung. | |
ATE77378T1 (de) | Verfahren zur herstellung von carbonsaeureamiden. | |
DE68913779D1 (de) | D-Amidase und Verfahren zur Herstellung von D-alpha-Alanin und/oder L-alpha-Alaninamid. | |
DE69031780D1 (de) | Verfahren zur Herstellung von (trans)-4-substituierten-DL-Prolinederivaten | |
ATE57912T1 (de) | Verfahren zur herstellung von anilinofumarat und 2,3-chinolindicarbonsaeure. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8366 | Restricted maintained after opposition proceedings |